+46%

est. 2Y upside i

EdTechSeries A

Robotic Automation for cancer diagnostics - Robotic Microscopes &…

Rank

#1065

Sector

MedTech

Est. Liquidity

~5Y

Data Quality

Data: Medium

Morphle Labs offers a moderate expected upside of ~45.8% over 2 years, but with higher risk due to incumbent competition.

Last updated: July 3, 2026

Bull (15%)+112%

Bull case: Exit at 5x forward revenue ($62.3M) driven by IPO window for profitable digital pathology company and strong IP portfolio. Net of 15% dilution, upside ~111.5%.

Base (55%)+66%

Base case: Exit at 4x forward revenue ($49.8M), converging to medtech comps. Net of 15% dilution, upside ~66.2%.

Bear (30%)-24%

Bear case: Multiple compresses to 2x ($24.9M) due to incumbent competition from Leica/Roche. Net of 15% dilution and preference overhang, downside ~24.4%.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Funding Intensity

19%

Total preferred liquidation preference of $5.15M represents 18.7% of entry valuation, a high overhang.

Dilution Risk

moderate

Current profitability reduces need for near-term funding, but capital-intensive business may require a Series B round within 24 months, estimating 15% dilution.

Secondary Liquidity

none

No secondary market activity reported; equity is illiquid.

View all 7 open roles at Morphle Labs →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Morphle Labs's data — designed to show you've done your homework.

  • 1

    “How would you defend against Leica's scale advantage in digital pathology?”

  • 2

    “What is the sales cycle for your hardware, and how do you plan to expand beyond the NCI?”

  • 3

    “Given the 2-year horizon, what are the liquidity expectations for employee equity?”

Community

Valuation Sentiment

Our model estimates +46% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.